Skip to main content
. 2023 Jan 4;13:1065038. doi: 10.3389/fneur.2022.1065038

Table 4.

Modification of clinical symptoms related OSA after treatment.

Patient characteristics (N = 99) At inclusion % (N) After 3 months % (N) After 6 months % (N) P
Symptoms at night
Snoring 61.6 (62) 44.4 (44) 6.0 (6) 0.005*; <0.00001**; <0.00001***
Difficulty for falling asleep 46.5 (47) 18.1 (18) 11.1 (11) <0.001*; <0.001**; 0.079***
Difficulty breathing during sleep 48.5 (48) 5.1 (5) 0.0 (0) <0.00001*; <0.00001**; <0.00001***
Disturbed sleep 76.8 (76) 73.7 (73) 56.6 (55) 0.310*; <0.001**; <0.003***
Frequent awake 38.3 (38) 9.1 (9) 0.0 (0) <0.00001*; <0.00001**; 0.001***
Nocturnal sweating 52.5 (52) 18.1 (18) 2.0 (2) <0.00001*; <0.00001**; <0.0001***
Enuresis 11.1 (11) 0.0 (0) 0.0 (0) <0.0001*; <0.0001**; N/A***
Daytime symptoms
Abnormal behavior 30.3 (30) 17.2 (17) 9.4 (9) 0.014*; <0.0001**; 0.046***
Irritable 47.4 (47) 37.3 (37) 26.3 (26) 0.075*; <0.001**; 0.046***
Agitated 29.3 (29) 8.1 (8) 0.0 (0) <0.0001*; <0.00001**; 0.001***
Sleepiness 26.3 (26) 13.1 (13) 4.1 (4) 0.010*; <0.0001**; 0.011***

*After 3 months vs. at inclusion; **After 6 months vs. at inclusion; ***After 6 months vs. after 3 months. NA, not applicable.